Alexion Pharmaceuticals, Inc. · Cheshire, CT United States (NASDAQ: ALXN)
| 352 Knotter Dr. | Phone: 203-272-2596 |
| Cheshire, CT | Fax: 203-271-8198 |
| 06410 | |
| United States | 
Map This Company |
Alexion Pharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause autoimmune, hematology, kidney, and neurology disorders, as well as cancers and other diseases. The company's first marketed antibody product, Soliris, has won approval in the US, Canada, and some European and Asia/Pacific countries for the treatment of a rare genetic blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). Alexion is also developing Soliris as a potential treatment for other autoimmune and inflammatory conditions. The company has additional development programs for cancer-fighting antibodies.
Alexion Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ALXN Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 792 |
Executives
69 executives listed for Alexion Pharmaceuticals, Inc.'s Cheshire, CT location.
| Chairman | Max Link | |
|---|---|---|
| CEO, Treasurer, and Director | Leonard Bell | |
| VP Site Operations and Engineering | Daniel Caron |